Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

BACKGROUND: The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehanna, Hisham, Robinson, Max, Hartley, Andrew, Kong, Anthony, Foran, Bernadette, Fulton-Lieuw, Tessa, Dalby, Matthew, Mistry, Pankaj, Sen, Mehmet, O'Toole, Lorcan, Al Booz, Hoda, Dyker, Karen, Moleron, Rafael, Whitaker, Stephen, Brennan, Sinead, Cook, Audrey, Griffin, Matthew, Aynsley, Eleanor, Rolles, Martin, De Winton, Emma, Chan, Andrew, Srinivasan, Devraj, Nixon, Ioanna, Grumett, Joanne, Leemans, C René, Buter, Jan, Henderson, Julia, Harrington, Kevin, McConkey, Christopher, Gray, Alastair, Dunn, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319250/
https://www.ncbi.nlm.nih.gov/pubmed/30449623
http://dx.doi.org/10.1016/S0140-6736(18)32752-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319250/
https://www.ncbi.nlm.nih.gov/pubmed/30449623
http://dx.doi.org/10.1016/S0140-6736(18)32752-1

Ejemplares similares